brimonidine tartrate profile

Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11236066
CHEMBL ID	2062257
SCHEMBL ID	34649
MeSH ID	M0065049

Synonym
AC-3599
agn-190342-lf
brimonidine tartrate
5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-6-quinoxalinamine tartrate
brimonidine tartarate
AKOS015895446
CHEMBL2062257
ocu300
ocu-300
SCHEMBL34649
59803-99-5
brimonidine d-tartarate
uk 14,304 tartrate
5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline tartrate
mfcd07773072
HMS3652B06
brimonidine tartrateuk 14,304 tartrate
HMS3677O18
5-bromo-6-(2-imidazolidinylideneamino) quinoxaline l-tartrate
zincarsenite
BCP28473
HMS3413O18
5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;2,3-dihydroxybutanedioic acid
A927815
SY065942

Excerpt	Reference	Relevance
" Various parameters were evaluated, including glaucoma medications (visit 1), IOP (visit 1-visit 3), and adverse events."	( The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. Abrams, C; Gornbein, J; Lee, DA, 2000)	0.31
" Both drug regimens appeared to be safe and were well tolerated."	( Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. David, R; Melamed, S, 2000)	0.31
" Study subjects within medication treatment groups were classified as to their use or nonuse of concurrent systemic beta-blockers, and mean intraocular pressure (IOP) reduction, adverse events, heart rate, and blood pressure were compared."	( Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman, JS, 2000)	0.31
" Adverse events and mean changes in heart rate and blood pressure from baseline were the primary safety variables."	( Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman, JS, 2000)	0.31
" Patients who were treated for less than three months, who failed therapy due to ineffectiveness of the medicine or an adverse event also were included."	( Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. Chopra, H; Day, DG; Holmes, KT; Kolker, AE; Konstas, AG; Lee, WH; Rieser, JC; Sharpe, ED; Stewart, WC, 2000)	0.31
" Safety and tolerability parameters included adverse events and quality-of-life measures (e."	( Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. Gornbein, JA; Lee, DA, 2001)	0.31
" Safety was measured by monitoring adverse events."	( A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Batoosingh, A; Felix, C; Mundorf, T; Whitcup, S; Williams, R, 2003)	0.32
" There were no statistically significant differences between the two groups in the overall incidence of adverse events."	( A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Batoosingh, A; Felix, C; Mundorf, T; Whitcup, S; Williams, R, 2003)	0.32
" Demographic data, reduction of IOP, safety and adverse events were obtained and analyzed."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
"0% patients in timolol group reported mild adverse events."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
" It has a safe systemic profile with minimum effect on the heart."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
" Being a newer drug, the whole spectrum of its adverse effects is not known."	( Dermatological side effects of brimonidine: a report of three cases. Ratan, J; Sodhi, PK; Verma, L, 2003)	0.32
" There have been occasional reports of systemic adverse effects in children including apparent central nervous system depression."	( Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Bowman, RJ; Cope, J; Nischal, KK, 2004)	0.32
"2% because of adverse side effects (two because of local irritation/allergy, two because of tiredness, and two because of fainting attacks)."	( Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Bowman, RJ; Cope, J; Nischal, KK, 2004)	0.32
" In this study, 18% of children had systemic adverse effects sufficient to necessitate stopping the drug."	( Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Bowman, RJ; Cope, J; Nischal, KK, 2004)	0.32
"Topical application of ocular drugs may cause serious adverse ocular or systemic side effects."	( Systemic side effects of ophthalmic drops. Levy, Y; Zadok, D, )	0.13
" Both agents were well tolerated with adverse events consistent with the package inserts."	( Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Fechtner, RD; Henry, C; Hughes, B; Lee, DA; Terry, S; Whitson, JT, 2004)	0.32
" Physicians should be aware of its side effect profile because of its general use in the paediatric population."	( Is brimonidine ophthalmic a safe therapy for infants? Daubert, GP, 2006)	0.33
" Patient discontinuations resulting from adverse events were similar for both groups and most of these were a result of signs or symptoms of ocular allergic reaction."	( The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Andrew, RM; Bergamini, MV; Bosworth, CF; Dickerson, JE; James, JE; Landry, TA; Moster, MR; Ochsner, KI; Silver, LH; Sullivan, EK; Wells, DT; Whitson, JT, 2006)	0.33
" A review of the literature reveals that when used in young infants brimonidine eye drops can potentially have toxic effects on the central nervous system (e."	( [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma]. Heimann, K; Hoernchen, H; Merz, U; Peschgens, T; Wenzl, T, 2007)	0.34
" Ocular burning was noted with dorzolamide more than any other adverse event with either drug."	( Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension. Craven, ER; Katz, LJ; Simmons, ST, 2007)	0.34
"We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management."	( Efficacy, safety, and current applications of brimonidine. Batiste, C; Fudemberg, SJ; Katz, LJ, 2008)	0.35
"Treatment-related adverse events (AEs) and discontinuations due to AEs."	( Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies. Batoosingh, AL; Cantor, LB; Hollander, DA; Liu, CC, 2009)	0.35
" A total of 143 patients experienced at least 1 treatment-related adverse event (AE; BBFC group, n=58, 26."	( Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. Goode, SM; McMenemy, MG; Nguyen, QH; Realini, T; Whitson, JT, 2013)	0.39
" Evaluations included severity of erythema based on Clinician's Erythema Assessment and Patient's Self-Assessment, as well as adverse events."	( Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M, 2013)	0.39
"5% was shown to be efficacious and safe for the treatment of erythema of rosacea in previous studies including a 4-week treatment phase."	( Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. Kempers, S; Leoni, M; Liu, H; Moore, A; Murakawa, G; Swinyer, L; Tauscher, A; Weiss, J, 2014)	0.4
" Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70%."	( Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Kim, CY; Kim, HK; Kim, JM; Kim, TW; Park, KH, 2016)	0.43
" The safety profile and risk of systemic toxic effects when brimonidine is used topically for hemostasis is unknown."	( Association of Central Nervous System Depression With Topical Brimonidine When Used for Hemostasis: A Serious Adverse Event. Schleichert, R; Shagalov, DR; Taylor, D; Weiss, E; Weiss, J, 2017)	0.46
"33%, gel can result in systemic central nervous system toxic effects when used as a hemostatic agent."	( Association of Central Nervous System Depression With Topical Brimonidine When Used for Hemostasis: A Serious Adverse Event. Schleichert, R; Shagalov, DR; Taylor, D; Weiss, E; Weiss, J, 2017)	0.46
" This study investigated the effects of brimonidine on auditory HCs that were also exposed to gentamicin, which is toxic to HCs."	( Brimonidine Protects Auditory Hair Cells from in vitro-Induced Toxicity of Gentamicin. Bodmer, D; Cortada, M; Levano, S, 2017)	0.46
" Safety assessments included adverse events (AEs), rebound redness on treatment discontinuation, comprehensive ophthalmic exams, and vital signs."	( Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness. DeCory, HH; Gomes, PJ; Sanfilippo, CM; Torkildsen, GL, 2018)	0.48
" The intraocular pressure (IOP), mean deviation value, and adverse drug reactions were evaluated."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.48
" There were no serious adverse drug reactions."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.48
"BBFC provides a significant IOP reduction and is a safe antiglaucoma medication for NTG patients."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.48
"Uveitis due to brimonidine is a rare adverse effect, but it must be known."	( Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Arciniegas-Perasso, CA; Clemente-Tomás, R; Duch-Samper, AM; García-Ibor, F; Hervás-Hernandis, JM; Ruiz-Del Río, N, 2018)	0.48
" Treatment-related adverse events were usually injection procedure-related."	( PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Augustin, AJ; Boyer, DS; Freeman, WR; Guo, Q; Kerr, KJ; Kuppermann, BD; López, FJ; Patel, SS; Schneider, S, 2021)	0.62
" Case series and prospective double-blind treatment studies also give evidence for the occurrence of several central nervous system adverse reactions."	( A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Cimolai, N, 2020)	0.56
" Ocular treatment-emergent adverse events occurred in 42."	( Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma. Kim, JM; Lee, JW; Maglambayan, J; Park, KH; Park, SW; Simonyi, S, 2021)	0.62
"Brimonidine had a similar side effect profile to the fix combination."	( Comparing the effects and safety of dorzolamide hydrochloride + timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification. Çakmak, K; Erbil, H; Korkmaz, Ş; Mesci, C, 2022)	0.72
"BBFC had satisfactory IOP-lowering effects without serious adverse reactions in patients who switched medications."	( Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications. Inoue, K; Ishida, K; Kunimatsu-Sanuki, S; Tomita, G, 2022)	0.72
" Secondary outcome measurements included visual acuity, IOP, drug tolerance, tear-film break-up time, hemodynamic changes including blood pressure and heart rates, and ocular adverse events."	( Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial. Kim, KE; Kim, Y; Lee, CK; Rho, S; Shin, J, 2023)	0.91

Excerpt	Reference	Relevance
" Drug elimination from aqueous humor was rapid initially with a half-life of 1 hr in rabbits, followed by a slower decline phase in pigmented rabbits."	( Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Acheampong, AA; Shackleton, M; Tang-Liu, DD, 1995)	0.29
" Statistical analysis was performed to compare the pharmacokinetic parameters between the control and disease animal models."	( Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown. Burke, J; Durairaj, C; Lin, T; Liu, Y; Shen, J, 2014)	0.4
" Therefore, extrapolation of ocular pharmacokinetic data obtained in normal animals to disease models for the purpose of pharmacokinetic/pharmacodynamic data analysis should be performed with caution."	( Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown. Burke, J; Durairaj, C; Lin, T; Liu, Y; Shen, J, 2014)	0.4
"A pharmacokinetic study was conducted to compare intraindividual systemic exposures after dermal application of BT gel (0·07%, 0·18% and 0·5%) under maximal use conditions in patients with moderate-to-severe facial erythema associated with rosacea, and administration of BT ophthalmic solution 0·2%."	( Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N, 2014)	0.4
"Patients who received BT ophthalmic solution 0·2% three times a day for 1 day had a mean Cmax of 54 ± 28 pg mL(-1) and a mean 0-24-h area under the curve (AUC0-24 h ) of 568 ± 277 pg h mL(-1) ."	( Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N, 2014)	0.4

Excerpt	Reference	Relevance
"To examine the relevance of concentration of benzalkonium chloride (BAK) on the cornea, we investigated the effects of latanoprost containing BAK alone and in combination with other antiglaucoma drug classes on corneal epithelium in vitro in a cultured rabbit corneal cell line (SIRC) and in vivo, using a corneal resistance device (CRD)."	( In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. Fukuda, M; Sasaki, H; Shibata, N; Shibata, S; Shibata, T; Sugiyama, K; Takeda, N, 2016)	0.43
"The purpose of this study is to evaluate the outcome of a series of patients with erythematotelangiectatic rosacea (ETR) affected by persistent erythema and varying degree of telangiectasias being treated with brimonidine alone or combined with a vascular laser based on the type of vascular components preliminarily evaluated by clinical and instrumental observation."	( Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component. Bhatt, K; Dall'Oglio, F; Lacarrubba, F; Luppino, I; Micali, G; Verzì, AE, 2018)	0.48

Excerpt	Reference	Relevance
" Taken together, the high alpha 2-adrenoceptor selectivity, ocular hypotensive efficacy, retinal bioavailability and neuroprotective properties make brimonidine an important addition to the field of antiglaucoma agents."	( Preclinical evaluation of brimonidine. Burke, J; Schwartz, M, 1996)	0.29
" Posttranscriptional regulation of eNOS protein may explain differences in NO bioavailability in juvenile pigs."	( Effect of puberty on coronary arteries from female pigs. Bracamonte, MP; Chatrath, R; Jayachandran, M; LaBreche, P; Miller, VM; Ronningen, KL; Severson, SR, 2003)	0.32
"The monoamine theory of depression proposes decreased bioavailability of monoamines, such as norepinephrine (NE), as the underlying cause of depression."	( An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Ignatowski, TA; Reynolds, JL; Spengler, RN; Sud, R, 2005)	0.33
" The pH difference between these 2 formulations seemed to exert no effect on brimonidine bioavailability or the tolerability of the solution."	( Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. Cantor, LB; Catoira-Boyle, Y; WuDunn, D; Yung, CW, )	0.13
"Various efforts have been made to improve the bioavailability and to prolong the residence time of eye drops."	( Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Shinde, UA; Singh, KH, 2011)	0.37
"The bioavailability of therapeutic agents from eye drops is usually limited due to corneal barrier functions and effective eye protective mechanisms."	( Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. Aburahma, MH; Mahmoud, AA, 2011)	0.37
"The poor bioavailability and therapeutic response exhibited by conventional eye drops due to rapid precorneal elimination of the drug may be overcome by the use of an in situ gelling systems that are instilled as drops into the eye and undergo a sol-to-gel transition in the cul-de-sac which improves patient compliance as the dosage regimen is one drop of the dosage form twice a day."	( Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system. Geethalakshmi, A; Jha, SK; Karki, R; Nikunj, B; Venkatesh, DP, 2012)	0.38
"To assess the relative bioavailability of topical BT gel in comparison with the ophthalmic BT solution."	( Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N, 2014)	0.4
"Topical drug administration to the eye is limited by low drug bioavailability due to its rapid clearance from the preocular surface."	( Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug. Choi, SY; Choy, YB; Chung, YJ; Jung, YE; Kim, MH; Kim, MJ; Kim, YK; Lee, SH; Lee, WS; Park, CG; Park, KH; Park, M, 2015)	0.42
"Conventional eye drops quickly move away from the surface of the eye; as a result, ocular bioavailability is very limited."	( Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy. Cho, IS; Cho, MO; Choy, YB; Huh, BK; Huh, KM; Kang, SW; Khatun, Z; Li, Z; Park, CG, 2016)	0.43
"Short residence time, poor bioavailability and poor permeability are the major problems for conventional eye drops treatment."	( Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 Barse, RK; Kokare, CR; Sharma, JP; Sharma, PK; Tagalpallewar, AA, 2018)	0.48
" However, the eye drops have limited effectiveness as a result of low drug bioavailability due to their rapid clearance from the preocular space."	( Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine. Choy, YB; Ha, A; Huh, BK; Kim, SN; Kim, YK; Ko, SA; Lee, SH; Park, CG; Park, KH; Park, YH, 2018)	0.48
" It enhances the ocular bioavailability by reducing the drug protein binding, increasing the corneal resident time, enhancing the drug permeability and providing a sustained drug release."	( Impact of Ocular Compatible Lipoids and Castor Oil in Fabrication of Brimonidine Tartrate Nanoemulsions by 3 Newton, MJ, 2018)	0.48
" This is direct evidence for better bioavailability of nanobrimonidine after topical administration."	( Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients. Barwal, I; Dada, T; Kumar, R; Yadav, SC, 2019)	0.51
"2% w/v brimonidine tartrate eye drop solution, which showed poor ocular bioavailability of 1-3%."	( In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma. Li, H; Xu, Y, 2022)	0.72

Excerpt	Relevance	Reference
" We therefore compared the dose-response curves of three alpha-2 adrenoceptor agonists, clonidine, UK 14,304 and 2,6-DMC."	( Opposite rank order of potency for alpha-2 adrenoceptor agonists on water and solute excretion in the rat: two sites and/or receptors? Blandford, DE; Li, P; Penner, SB; Smyth, DD, 1992)	0.28
" Pretreatment with the alpha 2 antagonist rauwolscine caused a 1 to 2 log unit right shift in the dose-response curve of UK in the CNM."	( Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Crosson, CE; DeVries, GW; Heath, AR; Potter, DE, 1992)	0.28
" The second approach was a detailed comparison between alpha 2-receptor occupancy by [3H] UK 14304 and the cyclic AMP inhibitory dose-response curve to this agonist in cells incubated also under conditions avoiding cyclic AMP breakdown."	( Evidence against the "spare" receptor nature of alpha 2-adrenoceptors in hamster white fat cells. Dieudonne, MN; Giudicelli, Y; Pecquery, R, 1990)	0.28
" However, the dose-response curves to phentolamine and the alpha-2 adrenoceptor agonist UK 14,304 on stimulus-induced overflow from the kidney were not significantly different after NE treatment."	( Effects of chronic norepinephrine administration on sympathetic neurotransmission in the isolated perfused rat kidney. Eikenburg, DC, 1990)	0.28
" Dose-response curves to noradrenaline were unaffected by prazosin (1 microM)."	( Alpha 2-adrenoceptor antisecretory responses in the rat jejunum. Dettmar, PW; Downing, OA; Roach, AG; Urquhart, CJ; Williams, RJ; Wilson, KA, 1990)	0.28
"Preincubation of HT29 cells with an alpha-2 adrenergic agonist resulted in a parallel rightward shift in the subsequent dose-response curve to 5-bromo-6-[2-imidazoline-2-yl-amino] quinoxaline (an alpha-2 adrenergic agonist) in inhibiting vasoactive intestinal peptide-stimulated cyclic AMP production."	( Desensitization of the alpha-2 adrenergic receptor in HT29 and opossum kidney cell lines. Bylund, DB; Jones, SB; Leone, SL, 1990)	0.28
" Cumulative dose-response curves of the alpha 1-agonists l-phenylephrine or cirazoline applied luminally in rat tail arteries and in side branches of canine femoral arteries were identical to those obtained by adventitial application in the intact arteries, and were not modified by removal of the endothelium (eliminating acetylcholine-induced dilations)."	( Endothelium-mediated dilations contribute to the polarity of the arterial wall in vasomotion induced by alpha 2-adrenergic agonists. Busse, R; Holtz, J; Kuon, E; Matsuda, H, )	0.13
" Dose-response curves to 5-bromo-6-(2-imidazoline-2-yl-amino)quinoxaline (UK 14,304) an alpha-2 adrenergic agonist, were generated in the absence and presence of three concentrations of various antagonists."	( Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. Bylund, DB; Ray-Prenger, C, 1989)	0.28
" A U-shaped dose-response curve to compounds with mixed alpha 2- and alpha 1-antagonist properties may be constructed, which emphasizes the importance of the dose-dependent selectivity of these antagonists at alpha 2- and alpha 1-receptors."	( Human vascular smooth muscle responses mediated by alpha 2 mechanisms in vivo and in vitro. Calvete, J; Hayes, R; Martin, G; Sever, P; Thom, S, 1985)	0.27
" Twenty-four hours after a single dose of desipramine (10 mg/kg, intraperitoneally) the inhibitory dose-response curves to either UK 14 304 or desipramine itself did not differ significantly from those seen in control animals, whereas both were displaced significantly to the right after 15 days pretreatment with desipramine."	( Effects of desipramine on stimulation-induced contractions of the vas deferens of rats pretreated either chronically with desipramine or acutely with idazoxan. Doxey, JC; Roach, AG; Samuel, J, 1985)	0.27
" Although administered in a dosage range 100 to 1000 times that of alpha-1 agonists, the alpha-2 agonists (B-HT 920, UK 14,304 and guanabenz) produced only minimal renal vasoconstriction before systemic pressor effects."	( In vivo assessment of rat renal alpha adrenoceptors. Gesek, FA; Strandhoy, JW; Wolff, DW, 1987)	0.27
"1 mg/kg) and of yohimbine (1 mg/kg) on the dose-response curves for cirazoline in the pithed rat, and for phenylephrine in the anaesthetized dog were compared, after various doses of phenoxybenzamine."	( Loss of selectivity of so-called selective alpha 1-adrenoceptor agonists after phenoxybenzamine. Gonçalves, J; Guimarães, S; Nunes, JP; Paiva, MQ, 1988)	0.27
" In rats treated with the ganglionic blocking agent, pentolinium, nicardipine produced parallel shifts to the right in the dose-response curves for phenylephrine but had no effect on maximal responses to phenylephrine."	( Greater vasodepressor sensitivity to nicardipine in spontaneously hypertensive rats (SHR) compared to normotensive rats. Armstrong, JM; Atkinson, J; Boillat, N; de Rivaz, JC; Fluckiger, JP; Fouda, AK; Piton, MC; Porchet, PA; Sautel, M; Sonnay, M, 1988)	0.27
", dose of WB-4101 isomer in mg/kg required to produce a 2-fold rightward shift in the dose-response curves of cirazoline and UK-14,304) obtained in vivo from Schild regressions, alpha 1/alpha 2 selectivity ratios were calculated."	( Blockade and postjunctional vascular alpha 1- and alpha 2-adrenoceptors in pithed rat by the enantiomers of WB-4101. Nelson, WL; Ruffolo, RR; Yaden, EL, 1983)	0.27
" In contrast, the dose-response curves to tiamenidine and clonidine were flatter and bell-shaped with maxima of 30 and 60 min, respectively."	( Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. Cavero, I; Doxey, JC; Roach, AG; Strachan, DA, 1983)	0.27
" Dose-response curves for the effects on the plasma noradrenaline concentration (stimulated pithed rabbits) were compared with previously obtained dose-response curves for depression of renal sympathetic nerve activity (conscious rabbits)."	( Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. Starke, K; Szabo, B; Urban, R, 1995)	0.29
" By contrast, phenylephrine-induced dose-response curves in rabbit aorta were largely unaffected by tyrosine kinase inhibitors at 50 microM."	( Alpha 2-adrenoceptor-mediated vasoconstriction requires a tyrosine kinase. Deth, RC; Jinsi, A, 1995)	0.29
" Dose-response curves were determined for the effects of rilmenidine as well as of the alpha-2 selective agonist UK 14304 [5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline] on blood pressure, heart rate, renal postganglionic sympathetic nerve activity and the plasma norepinephrine concentration."	( Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors? Starke, K; Szabo, B; Urban, R, 1994)	0.29
" In agonist dose-response studies, WO caused a noncompetitive inhibition of both alpha 1R and alpha 2R responses, but was more potent against alpha 2R."	( Effects of wortmannin on alpha-1/alpha-2 adrenergic receptor-mediated contractile responses in rabbit vascular tissues. Deth, RC; Waen-Safranchik, VI, 1994)	0.29
"The authors explored the empirical dosing requirement for administration of an alpha 2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360 degrees argon laser trabeculoplasty (ALT)."	( The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ, 1993)	0.29
"This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine."	( The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ, 1993)	0.29
" There was little difference in efficacy between the three dosing regimens of brimonidine."	( The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ, 1993)	0.29
" Prazosin (10(-8) M - 10(-5) M) displaced agonist dose-response curves to the right."	( Characterization of alpha-adrenoceptor subtype(s) mediating vasoconstriction in the perfused rabbit ovarian vascular bed. Oriowo, MA; Williams, KI; Yousif, M, 1996)	0.29
" Changes in vessel internal diameter were measured and dose-response curves (DRC) for each vasoactive agent were determined."	( Nitric oxide inhibition simulates the enhancement of alpha 1 agonist-induced vasoconstriction in diabetes. Dresner, LS; Mueller, CM; Ponomarenko, IN; Wait, RB; Wang, SP; West, MW, 1997)	0.3
" Yohimbine pretreatment resulted in a rightward shift of the dose-response curves (DMET > CLON > UK)."	( Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Buerkle, H; Yaksh, TL, 1998)	0.3
" When dosed according to labeling, latanoprost had the lowest cost of therapy at $0."	( Daily cost of newer glaucoma agents. Hudgins, AC; Pruitt, CA; Sine, C; Stewart, WC, 1999)	0.3
"This study suggests latanoprost dosed daily in the evening statistically reduces intraocular pressure more during daytime and evening hours than brimonidine dosed twice daily."	( The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Day, DG; Latham, KE; Schuhr, J; Stewart, JA; Stewart, WC, 2001)	0.31
" Brimonidine reduced the rate of RGC loss in the calibrated rat optic nerve injury model even when dosed 12 and 24 hours before injury, consistent with a long-term enhancement of RGC resistance to stress."	( Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Gil, DW; Wheeler, LA; WoldeMussie, E, 2001)	0.31
" Each treatment period consisted of 6 weeks of chronic dosing followed by a diurnal curve for the intraocular pressure measured at 08:00, 10:00, 16:00, 18:00, 20:00, 22:00, and 24:00 hours."	( Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Holmes, KT; Konstas, AG; Stangos, NT; Stewart, WC; Tersis, I; Topouzis, F, 2001)	0.31
") caused dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920."	( alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. Hashimoto, A; Imaizumi, T; Kambe, T; Kishi, M; Mori, T; Nakazawa, T; Orito, K, 2001)	0.31
" Single and multiple dosing led to a similar drug distribution, with higher levels of brimonidine measured in pigmented tissues after multiple dosing."	( Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Acheampong, AA; Burke, J; John, B; Shackleton, M; Tang-Liu, D; Wheeler, L, 2002)	0.31
"The purpose of this study was to investigate the dose-response effects of topically administered brimonidine (BMD) on retinal ganglion cell (RGC) survival, short and long periods of time after transient retinal ischemia."	( Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Aguilera, ME; Lafuente, MP; Mayor, S; Miralles de Imperial, J; Vidal-Sanz, M; Villegas-Pérez, MP, 2002)	0.31
" In fetal, but not adult, MCA, UK-14304 induced a significant decrease in pD(2) for the phenylephrine dose-response relation."	( Pre- and postjunctional alpha(2)-adrenergic receptors in fetal and adult ovine cerebral arteries. Bishai, JM; Buchholz, JN; Gheorghe, CP; Longo, LD; Meulenaar, R; Nijland, R; Penninga, L; Zhang, L; Zhao, Y, 2002)	0.31
"A single dosage of brimonidine tartrate ophth solution (0."	( Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Cantor, LB; Gao, H; Qiao, X; WuDunn, D, 2002)	0.31
"The subjects in this prospective, double-masked, crossover comparison were dosed 15 min prior to treadmill testing."	( Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Jackson, AL; Stewart, JA; Stewart, WC, 2002)	0.31
"Rates of medication discontinuation reflect factors including effectiveness, tolerability, cost, and dosing frequency."	( Discontinuation rates of topical glaucoma medications in a managed care population. Cho, J; Mullins, CD; Shaya, FT; Wong, W, 2002)	0.31
" AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6."	( Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors. Burgdorf, C; Engelhardt, A; Kurz, T; Richardt, G; Schäfer, U, 2002)	0.31
" Clinical dosing of the topical formulation of brimonidine results in brimonidine concentrations in the posterior segment that are sufficient for both pharmacological activity at alpha-2 adrenergic receptors and neuroprotection."	( Role of alpha-2 agonists in neuroprotection. Lai, R; Wheeler, L; WoldeMussie, E, 2003)	0.32
" Children are at greater risk for systemic side effects because ocular dosing is not weight-adjusted, and infants are especially vulnerable as a consequence of the inability to efficiently metabolize the drug, and/or an immature blood-brain barrier."	( Systemic side effects of ophthalmic drops. Levy, Y; Zadok, D, )	0.13
" However, unoprostone, but not brimonidine, decreased IOP over the complete 12-hour daytime dosing cycle."	( The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. Day, DG; Jenkins, J; Stewart, JA; Stewart, WC, 2004)	0.32
"Fixed combination latanoprost/timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine/timolol."	( A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C, 2004)	0.32
" Intraocular pressure (IOP) was measured at 08:00 (trough) and 10:00, 18:00, and 20:00 hours after dosing at each baseline and at the end of each treatment period."	( Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Beischel, CJ; Day, DG; Rhodes, JS; Sharpe, ED; Stewart, JA; Stewart, WC, 2004)	0.32
" Topical brimonidine purite in this dosage was unsuccessful in preventing second eye involvement in recently monocularly-symptomatic LHON."	( Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Bhatti, MT; Biousse, V; Chen, K; David, R; Farris, BK; Hamilton, SR; Keaney, RP; Lesser, RL; Newman, NJ; Newman, SA; Turbin, RE, 2005)	0.33
" IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12."	( 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi, FJ, )	0.13
" Its simplified dosing regimen has the potential to improve compliance."	( 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi, FJ, )	0.13
" Brimonidine is not dosed by weight and therefore paediatric patients may be at increased risk for systemic toxicity."	( Is brimonidine ophthalmic a safe therapy for infants? Daubert, GP, 2006)	0.33
"15% preserved with chlorine dioxide (brimonidine P) dosed 3 times daily and were followed up for 6 months."	( The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Andrew, RM; Bergamini, MV; Bosworth, CF; Dickerson, JE; James, JE; Landry, TA; Moster, MR; Ochsner, KI; Silver, LH; Sullivan, EK; Wells, DT; Whitson, JT, 2006)	0.33
"To evaluate the 24-h intraocular pressure (IOP) control of brimonidine/timolol fixed combination (BTFC) versusthe unfixed combination of its individual components, each dosed twice daily, in patients with primary open-angle glaucoma or ocular hypertension."	( Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Georgiadou, I; Kaltsos, K; Katsimpris, IE; Konstas, AG; Kordelou, A; Nelson, LA; Stewart, WC, 2008)	0.35
"15%, both dosed twice a day for 4 weeks."	( Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. Hong, S; Kim, CY; Seong, GJ, 2007)	0.34
" For prostaglandins, dosing time was suggested in the morning by 18 (36%) ophthalmologists and in the evening by 24 (48%) (p=0."	( Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Kruft, B; Nelson, LA; Stewart, JA; Stewart, WC, )	0.13
" However, the fixed dosing may be a disadvantage in some cases."	( Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Katz, LJ; Razeghinejad, MR; Sawchyn, AK, 2010)	0.36
" In-vivo experiments showed that it was possible to prolong the drug release over a period of 8 hr, on topical instillation of BT loaded nanoparticles to albino rabbits, hence reducing the dosage frequency."	( Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate. Shinde, UA; Singh, KH, 2010)	0.36
" In 65 patients (97%), at least 1 dosing interval exceeded 24 hours."	( Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring. Bron, AM; Creuzot-Garcher, CP; Diestelhorst, M; Hermann, MM, 2011)	0.37
"To assess the impact of open versus masked adherence monitoring on adherence with topical brimonidine using two different dosing schedules."	( Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Diestelhorst, M; Georgopoulos, G; Hermann, MM; Muether, PS; Papaconstantinou, D, 2011)	0.37
" Adherence calculations comprised dosing intervals, adherence rate and time covered."	( Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Diestelhorst, M; Georgopoulos, G; Hermann, MM; Muether, PS; Papaconstantinou, D, 2011)	0.37
" Hence, the lyophilized vesicles, when dispersed in viscous carbopol solution, had the potential in reducing dosing frequency and could improve patient compliance."	( Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation. Maiti, S; Mondol, R; Paul, S; Ray, S; Sa, B, 2011)	0.37
" These results suggest that BT loaded CS nanoparticles could help to reduce dosage frequency by sustained drug release in the treatment of glaucoma."	( Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Shinde, UA; Singh, KH, 2011)	0.37
"The poor bioavailability and therapeutic response exhibited by conventional eye drops due to rapid precorneal elimination of the drug may be overcome by the use of an in situ gelling systems that are instilled as drops into the eye and undergo a sol-to-gel transition in the cul-de-sac which improves patient compliance as the dosage regimen is one drop of the dosage form twice a day."	( Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system. Geethalakshmi, A; Jha, SK; Karki, R; Nikunj, B; Venkatesh, DP, 2012)	0.38
"005% (n = 75, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks."	( Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM, 2012)	0.38
" Based on the optimized formulation, triple-layered ocular inserts (reservoir type) of dual drug were prepared by solvent casting technique with an objective of reducing the frequency of administration, obtaining controlled release and greater therapeutic efficacy, preservative free dosage form for the treatment of glaucoma."	( Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts. Appapurapu, AK; Ravindran, VK; Repala, S; Subadhra, S, 2014)	0.4
" Brimonidine tartrate (BT), a common glaucoma medication, requires dosing every 8-12 h, with up to 97% of patients not taking it as prescribed."	( 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres. Conner, IP; Fedorchak, MV; Little, SR; Medina, CA; Schuman, JS; Wingard, JB, 2014)	0.4
"2% monotherapy, all dosed 2 times per day (BID)."	( Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Aung, T; Branch, JD; Goldberg, I; Hernandez Paredes, TJ; Laganovska, G; Tsorbatzoglou, A, 2014)	0.4
" Thus, the developed nanobrimonidine has the potential to improve the efficacy, reduce dosage and frequency, and improve delivery to the anterior chamber of the eye."	( Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients. Barwal, I; Dada, T; Kumar, R; Yadav, SC, 2019)	0.51
"Timolol is a non-cardioselective beta blocker and has different combined ophthalmic dosage forms for treatment of glaucoma."	( A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol. El Abass, SA; Elmansi, HM; Ibrahim, FA, 2019)	0.51
" Among the latter, a dose-response phenomenon is evident."	( A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Cimolai, N, 2020)	0.56
" Significant improvements in near vision were observed only during the 1-2 h period after dosing when miosis peaked."	( Time-course of the visual Impact on presbyopes of a low dose miotic. Bradley, A; Dibas, M; Gil, D; Kollbaum, P; Meyer, D; Perron, L; Rickert, M; Xu, R, 2021)	0.62
" For many chronic ocular diseases, patient adherence to eye drop dosing regimens and the need for frequent intraocular injections are significant barriers to effective disease management."	( Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery. Anders, NM; Appell, MB; Chou, RT; Cummings, MP; Davison, C; Edwards, M; Ensign, LM; Hanes, J; Hemingway, A; Hsueh, HT; Kim, YC; Kolodziejski, P; Kwon, H; Leo, KT; Liyanage, W; Mozzer, A; Pejavar, J; Pitha, I; Rai, U; Rompicharla, SVK; Sista, M, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	135 (8.99)	18.7374
1990's	452 (30.11)	18.2507
2000's	462 (30.78)	29.6817
2010's	348 (23.18)	24.3611
2020's	104 (6.93)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	282 (17.89%)	5.53%
Reviews	85 (5.39%)	6.00%
Case Studies	124 (7.87%)	4.05%
Observational	2 (0.13%)	0.25%
Other	1,083 (68.72%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (160)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study [NCT03323164]	Phase 4	35 participants (Actual)	Interventional	2017-07-10	Completed
A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma [NCT03193333]	Phase 3	51 participants (Anticipated)	Interventional	2017-11-06	Recruiting
Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea [NCT03048058]	Phase 4	20 participants (Actual)	Interventional	2016-05-05	Completed
Enhanced Pupil Dilation in Patients Taking Alpha-Blockers for Potential Treatment of Intraoperative Floppy Iris Syndrome [NCT03760185]	Phase 2	13 participants (Actual)	Interventional	2019-01-04	Completed
Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature [NCT01201551]		40 participants (Actual)	Interventional	2011-06-30	Completed
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients With Dry Eye Disease (DED) [NCT03785340]	Phase 3	252 participants (Actual)	Interventional	2018-12-03	Completed
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED) [NCT03418727]	Phase 2	84 participants (Actual)	Interventional	2017-09-06	Completed
Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution Manufactured by Laboratorios Sophia, Previous Treatment With Krytantek Ofteno ®, in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension. [NCT03257813]	Phase 3	60 participants (Actual)	Interventional	2016-04-01	Completed
Circadian Rhythms of Aqueous Humor Dynamics in Subjects With Ocular Hypertension Using Brimonidine [NCT01144494]	Early Phase 1	35 participants (Actual)	Interventional	2010-08-01	Completed
Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents [NCT02140450]		70 participants (Actual)	Interventional	2012-02-29	Completed
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03139708]	Phase 1	5 participants (Actual)	Interventional	2016-09-30	Completed
Effect of Brimonidine on Corneal Thickness [NCT01250236]		10 participants (Anticipated)	Observational	2010-12-31	Recruiting
[NCT01284166]	Phase 3	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to Study was never initiated due to company decision. No study subjects were ever enrolled or treated.)
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease [NCT03591874]	Phase 3	59 participants (Actual)	Interventional	2018-12-23	Terminated(stopped due to Primary endpoint was not met.)
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists [NCT03497442]	Early Phase 1	20 participants (Actual)	Interventional	2018-07-12	Completed
Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops [NCT03220490]		65 participants (Anticipated)	Interventional	2017-11-01	Recruiting
Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension [NCT01062971]	Phase 2	124 participants (Actual)	Interventional	2006-02-28	Completed
24-hr Intraocular Pressure Control With Brinzolamide 1% / Brimonidine 0.2% Ophthalmic Suspension vs Vehicle [NCT02770248]	Phase 4	162 participants (Actual)	Interventional	2016-05-23	Completed
Mirvaso® Utilisation and Patient Satisfaction Evaluation [NCT02637232]		301 participants (Actual)	Observational	2015-10-31	Completed
A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs. Monotherapy With Carbachol Topical Ophthalmic Solution in Subjects Wit [NCT04774237]	Phase 2	81 participants (Actual)	Interventional	2021-03-24	Completed
[NCT03508869]		5 participants (Actual)	Interventional	2016-09-27	Terminated(stopped due to sponsor asked site to suspend study.)
The Effect of Topical Brimonidine on the Hemodynamics of the Optic Nerve Head and Retinochoroidal Circulation in Patients of Primary Open Angle Glaucoma Using Optical Coherence Tomography Angiography [NCT05474716]	Phase 4	41 participants (Actual)	Interventional	2020-05-01	Completed
Study of Safety and IOP Lowering Efficacy of Transdermal Brimonidine Therapy [NCT01345448]	Phase 2	22 participants (Anticipated)	Interventional	2011-04-30	Recruiting
Hypotensive Efficacy of Topical Prophylaxis for Intraocular Pressure Spikes Following Intravitreal Injections of Anti-vascular Endothelial Growth Factor Agents [NCT03513172]		55 participants (Actual)	Interventional	2016-12-15	Completed
Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma [NCT01310777]	Phase 3	771 participants (Actual)	Interventional	2011-05-31	Completed
A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Thr [NCT01297920]	Phase 3	1,062 participants (Actual)	Interventional	2011-03-31	Completed
A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) [NCT02863705]	Phase 4	118 participants (Actual)	Interventional	2016-07-05	Completed
Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism [NCT00712777]		0 participants (Actual)	Interventional	2008-03-31	Withdrawn
The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma [NCT04205201]	Phase 2	80 participants (Actual)	Interventional	2018-06-25	Completed
Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs [NCT00675207]	Phase 4	120 participants (Actual)	Interventional	2006-01-31	Completed
[NCT00822055]	Phase 4	140 participants (Actual)	Interventional	2005-05-31	Completed
Safety and IOP-Lowering Efficacy of Brinzolamide/Brimonidine Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma and/or Ocular Hypertension [NCT00961649]	Phase 2	195 participants (Actual)	Interventional	2009-10-31	Terminated
Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients. [NCT04702789]	Phase 4	28 participants (Actual)	Interventional	2021-10-19	Terminated(stopped due to For interests of sponsor.)
Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT02339584]	Phase 3	493 participants (Actual)	Interventional	2015-04-14	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma [NCT00981786]	Phase 4	51 participants (Actual)	Interventional	2009-08-31	Completed
Comparison of Selective Laser Trabeculoplasty With Prostaglandin Analogues for Lowering Intraocular Pressure in Eyes With Primary Angle Closure Glaucoma [NCT01004900]	Phase 3	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery [NCT00800423]	Phase 3	150 participants (Anticipated)	Interventional	2009-01-31	Not yet recruiting
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1% [NCT04007276]	Phase 4	60 participants (Anticipated)	Interventional	2025-11-10	Not yet recruiting
[NCT00651612]	Phase 3	604 participants (Actual)	Interventional	2005-11-30	Completed
Synergistic Use of Pilocarpine-Brimonidine-Oxymetazoline to Control Presbyopia Symptoms [NCT05006898]	Phase 1	11 participants (Actual)	Interventional	2020-06-01	Completed
Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®, Elaborated by Sophia Laboratories, S.A. of C.V. on the Ocular Surface of Ophthalmologically and Clinicall [NCT03966365]	Phase 1	24 participants (Actual)	Interventional	2019-05-02	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma [NCT00972257]	Phase 4	64 participants (Actual)	Interventional	2009-01-31	Completed
Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glau [NCT00698945]	Phase 4	40 participants (Anticipated)	Interventional	2008-06-30	Completed
A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients With Rosacea [NCT02602470]		206 participants (Actual)	Observational	2015-01-08	Completed
Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma [NCT00800540]	Phase 4	35 participants (Actual)	Interventional	2009-02-28	Completed
Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE) [NCT02568111]	Phase 4	0 participants (Actual)	Interventional	2016-02-29	Withdrawn
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Mult [NCT04647461]	Phase 4	61 participants (Actual)	Interventional	2019-03-20	Active, not recruiting
[NCT01217606]	Phase 3	185 participants (Actual)	Interventional	2011-01-31	Completed
[NCT00652483]	Phase 3	433 participants (Actual)	Interventional	2003-05-31	Completed
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results [NCT00804921]	Phase 2	0 participants	Interventional		Completed
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection [NCT00864838]	Phase 2	56 participants (Actual)	Interventional	2008-06-30	Completed
[NCT00822081]	Phase 4	140 participants (Actual)	Interventional	2005-01-31	Completed
A Prospective Study to Evaluate the Effect of Preoperative Topical Brimonidine Tartrate 0.2% (Allergan, Irvine, CA) on Intraocular Pressure (IOP) of Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (RALP) [NCT02818816]	Phase 4	26 participants (Actual)	Interventional	2016-02-29	Completed
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03959176]	Phase 4	13 participants (Actual)	Interventional	2019-07-20	Completed
[NCT00168363]	Phase 3	207 participants (Actual)	Interventional	2005-01-31	Completed
Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Treatment in Encapsulated Blebs: a 12-month Prospective Study [NCT01887223]	Phase 2	40 participants (Actual)	Interventional	2010-05-31	Completed
[NCT00413751]		20 participants	Observational		Completed
Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension [NCT01297517]	Phase 3	1,001 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema. [NCT02856919]	Phase 4	101 participants (Actual)	Interventional	2016-06-13	Completed
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia [NCT05431543]	Phase 2	58 participants (Actual)	Interventional	2022-08-06	Completed
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty [NCT00567411]		43 participants (Anticipated)	Interventional	2006-08-31	Recruiting
A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension [NCT03450629]	Phase 3	682 participants (Actual)	Interventional	2018-09-13	Completed
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter [NCT02214680]	Phase 2	25 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients [NCT06078592]	Phase 4	60 participants (Actual)	Interventional	2021-10-08	Completed
[NCT00652106]	Phase 3	432 participants (Actual)	Interventional	2003-06-30	Completed
Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations: A Prospective, Open-label, Cohort Study [NCT02764411]	Phase 3	6 participants (Actual)	Interventional	2016-06-30	Terminated(stopped due to Poor enrollment, lack of feasibility)
The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema [NCT02718547]		25 participants (Anticipated)	Interventional	2017-03-26	Recruiting
Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias [NCT02761174]	Phase 4	19 participants (Actual)	Interventional	2016-03-13	Completed
A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular [NCT00706927]		16 participants (Actual)	Interventional	2006-01-31	Completed
Effect of Brimonidine 0.15% on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Tension Glaucoma [NCT01105065]		46 participants (Actual)	Interventional	2010-03-31	Completed
[NCT00332345]	Phase 2	73 participants (Actual)	Interventional	1999-07-31	Completed
Short-term Intraocular Pressure Control After YAG Iridotomy - Comparison Between Brimonidine 0.1% vs. 0.2% [NCT01417858]		50 participants (Anticipated)	Interventional	2010-11-30	Recruiting
The Effect if Brimonidine 0.15% on the Development of Subconjunctival Hemorrhage Following Femtosecond Laser Assisted Cataract Surgery [NCT04633954]		56 participants (Actual)	Interventional	2019-06-06	Completed
Evaluation of Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model [NCT05579730]	Phase 3	187 participants (Actual)	Interventional	2022-11-18	Completed
Topical Brimonidine vs Argon Laser Trabeculoplasty in Progressing Human Glaucoma. A Prospective Randomized Clinical Trial. [NCT00466479]	Phase 4	50 participants	Interventional	1999-08-31	Completed
[NCT00440141]	Phase 4	40 participants (Actual)	Interventional	2006-07-31	Completed
Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01309204]	Phase 3	1,184 participants (Actual)	Interventional	2011-05-31	Completed
[NCT01241240]	Phase 3	192 participants (Actual)	Interventional	2011-03-31	Completed
[NCT01229410]	Phase 1	24 participants (Actual)	Interventional	2010-12-31	Completed
The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy [NCT01255306]		60 participants (Actual)	Observational	2010-04-30	Completed
The Effect of Brimonidine Tartrate on Subconjunctival Hemorrhage During Pterygium Surgery [NCT04683159]		66 participants (Anticipated)	Interventional	2021-02-28	Not yet recruiting
Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis [NCT05591755]	Phase 3	228 participants (Actual)	Interventional	2022-10-22	Completed
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia [NCT05135286]	Phase 3	450 participants (Anticipated)	Interventional	2022-03-15	Recruiting
[NCT01151904]	Phase 4	17 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Difficulty with patient recruitment)
A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Study to Evaluate the Drug-drugs Interaction Between Dorzolamide and Brimonidine in Healthy Korean Male Volunteers [NCT02967614]	Phase 1	32 participants (Actual)	Interventional	2016-12-31	Completed
INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE [NCT00347035]	Phase 4	0 participants	Interventional		Terminated
Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial [NCT00435058]		54 participants	Interventional	2005-09-30	Completed
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost [NCT00348400]	Phase 4	0 participants	Interventional		Completed
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients. [NCT00352807]		22 participants	Interventional	2005-02-28	Completed
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to Simbrinza® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes [NCT04944290]	Phase 3	447 participants (Actual)	Interventional	2021-05-28	Completed
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia [NCT05270863]	Phase 3	182 participants (Actual)	Interventional	2022-03-30	Completed
[NCT00332384]	Phase 3	573 participants (Actual)	Interventional	2000-01-31	Completed
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Palpebral Fissure Height [NCT03782701]	Phase 4	43 participants (Actual)	Interventional	2019-06-18	Completed
Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves [NCT01535768]	Phase 4	150 participants (Anticipated)	Interventional	2012-02-29	Recruiting
A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Mon [NCT00121147]		200 participants	Interventional	2003-09-30	Completed
Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans [NCT00275756]		0 participants (Actual)	Interventional	2008-09-30	Withdrawn
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost. [NCT00402493]		51 participants (Actual)	Interventional	2006-12-31	Completed
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00061529]	Phase 3	0 participants	Interventional	2003-01-31	Completed
[NCT00457795]	Phase 4	15 participants (Actual)	Interventional	2006-12-31	Completed
[NCT00693485]	Phase 2	70 participants (Actual)	Interventional	2008-09-30	Completed
A Phase II, Single-Center, Two-Way Crossover Relative Systemic Bioavailability Study of Col-118 Administered Topically as a 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2% Administered to the Eye in Subjects With Moderate to Severe Erythematous [NCT00697541]	Phase 2	20 participants (Actual)	Interventional	2008-05-31	Completed
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD [NCT00658619]	Phase 2	119 participants (Actual)	Interventional	2008-05-01	Completed
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects [NCT00735449]	Phase 4	204 participants (Actual)	Interventional	2008-07-31	Completed
Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy [NCT01726075]	Phase 2/Phase 3	450 participants (Actual)	Interventional	2013-02-28	Completed
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma [NCT00869141]	Phase 4	52 participants (Actual)	Interventional	2009-03-31	Completed
[NCT01987752]		732 participants (Actual)	Observational	2009-01-31	Completed
[NCT02385240]	Phase 3	552 participants (Actual)	Interventional	2015-03-31	Completed
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia [NCT05936489]	Phase 1	30 participants (Actual)	Interventional	2023-07-06	Completed
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult [NCT05815758]		511 participants (Actual)	Observational	2023-04-20	Completed
A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT01687426]	Phase 1	15 participants (Actual)	Interventional	2012-09-30	Completed
A Multicenter, Double-Masked, 2-Arm Parallel Group Study Comparing the Effect of Brimonidine 0.2% Versus Timolol 0.5% on Visual Field Stability in Patients With Low-Pressure Glaucoma [NCT00317577]	Phase 2	160 participants	Interventional	1998-12-31	Completed
[NCT00332436]	Phase 3	586 participants (Actual)	Interventional	1999-12-31	Completed
Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise [NCT00312416]	Phase 4	18 participants	Interventional	2004-02-29	Completed
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost [NCT01937299]	Phase 4	307 participants (Actual)	Interventional	2013-10-31	Completed
Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects [NCT05753189]	Phase 3	361 participants (Actual)	Interventional	2023-02-21	Active, not recruiting
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia [NCT05728944]	Phase 3	229 participants (Actual)	Interventional	2023-04-24	Active, not recruiting
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia [NCT05656027]	Phase 3	469 participants (Actual)	Interventional	2022-12-19	Active, not recruiting
[NCT01170884]	Phase 4	121 participants (Actual)	Interventional	2009-12-31	Completed
Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea [NCT01885000]	Phase 3	92 participants (Actual)	Interventional	2013-07-01	Completed
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia [NCT06045299]	Phase 3	300 participants (Anticipated)	Interventional	2023-09-27	Recruiting
[NCT01229462]		238 participants (Actual)	Interventional	2010-10-31	Completed
Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients [NCT01446497]	Phase 4	22 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy [NCT03192826]	Phase 4	79 participants (Actual)	Interventional	2016-06-20	Completed
A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With No [NCT03150160]	Phase 4	1 participants (Actual)	Interventional	2017-09-21	Completed
A Descriptive Comfort Study of Brinzolamide 1% / Brimonidine Tartrate 0.2% Fixed Combination Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension and Brimonidine Tartrate 0.2% Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hype [NCT01426867]	Phase 2	103 participants (Actual)	Interventional	2011-09-30	Completed
MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study) [NCT02249065]	Phase 4	205 participants (Actual)	Interventional	2014-09-30	Completed
[NCT01525173]	Phase 4	137 participants (Actual)	Interventional	2012-01-31	Completed
A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea [NCT01659853]	Phase 3	70 participants (Actual)	Interventional	2012-09-30	Completed
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study [NCT02147691]	Phase 4	22 participants (Actual)	Interventional	2014-05-31	Completed
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration [NCT02087085]	Phase 2	310 participants (Actual)	Interventional	2014-05-09	Terminated
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Pediatric, Adult, and Geriatric Subjects [NCT01959243]	Phase 3	507 participants (Actual)	Interventional	2014-02-22	Completed
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) [NCT02975557]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Slow accrual of subjects. May take longer than expected to complete the trial.)
Comparison of Pilocarpine, Brimonidine, Oxymetazoline, Hialuronic Acid, Bromfenac Ophthalmic Compound With Pilocarpine and Brimonidine to Improve Uncorrected Visual Acuity in Healthy Presbyopic Individuals [NCT05001243]	Phase 1	11 participants (Anticipated)	Interventional	2021-08-10	Recruiting
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects. [NCT02039765]	Phase 1	12 participants (Actual)	Interventional	2014-02-28	Completed
Half-Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand-Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN) [NCT03173365]	Phase 2	2 participants (Actual)	Interventional	2017-07-10	Terminated(stopped due to It is no longer practicable to complete the trial)
[NCT00661479]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2008-07-31	Completed
[NCT00972374]	Phase 2	44 participants (Actual)	Interventional	2009-11-30	Completed
[NCT00811564]	Phase 4	148 participants (Actual)	Interventional	2008-12-31	Completed
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG) [NCT00824824]		21 participants (Actual)	Interventional	2009-01-31	Completed
[NCT01863953]	Phase 2	112 participants (Actual)	Interventional	2013-06-30	Completed
Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia [NCT05006911]	Phase 1	11 participants (Anticipated)	Interventional	2021-08-14	Recruiting
Efficacy of Intraoperative Brimonidine for Hemostasis During Eyelid Surgery [NCT05480098]	Phase 4	100 participants (Anticipated)	Interventional	2022-05-26	Recruiting
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia [NCT05294328]	Phase 2	62 participants (Actual)	Interventional	2022-05-05	Completed
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, [NCT01216943]	Phase 3	126 participants (Actual)	Interventional	2010-11-30	Completed
[NCT00811850]	Phase 4	15 participants (Actual)	Interventional	2008-12-31	Completed
[NCT02003534]	Phase 4	376 participants (Actual)	Interventional	2010-07-31	Completed
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue [NCT01937312]	Phase 4	282 participants (Actual)	Interventional	2013-10-31	Completed
A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Re [NCT01959230]	Phase 3	60 participants (Actual)	Interventional	2013-11-07	Completed
Effect of Topical Prophylaxis With Brinzolamide-brimonidine Fixed Combination on Intraocular Pressure Elevation After Intravitreal Injections of Anti-vascular Endothelial Growth Factors [NCT04523844]		47 participants (Actual)	Interventional	2020-05-11	Completed
Effectiveness of Pilocarpine and Brimonidine to Improve Near Visual Acuity in Patients With Monofocal Intraocular Lenses [NCT03825081]	Early Phase 1	33 participants (Anticipated)	Interventional	2019-01-21	Recruiting
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification [NCT03494257]		62 participants (Actual)	Interventional	2017-09-04	Completed
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical [NCT02289352]	Phase 3	462 participants (Actual)	Interventional	2014-07-31	Completed
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue [NCT02419508]	Phase 4	290 participants (Actual)	Interventional	2015-08-07	Completed
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) [NCT02730871]	Phase 4	173 participants (Actual)	Interventional	2016-06-24	Terminated(stopped due to Enrollment Challenges)
The Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation With Lumify® 0.025% in Adult Subjects With Ocular Redness [NCT05360784]	Phase 3	380 participants (Actual)	Interventional	2022-05-13	Completed
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) [NCT01275105]	Phase 2	68 participants (Actual)	Interventional	2011-01-31	Completed
A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects [NCT01675609]	Phase 2	57 participants (Actual)	Interventional	2012-08-31	Completed
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy [NCT01978600]	Phase 4	89 participants (Actual)	Interventional	2013-10-31	Completed
Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea [NCT02616250]	Phase 4	190 participants (Actual)	Interventional	2015-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00457795 (4) [back to overview]	Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
NCT00457795 (4) [back to overview]	Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4
NCT00457795 (4) [back to overview]	Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4
NCT00457795 (4) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
NCT00658619 (5) [back to overview]	Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
NCT00658619 (5) [back to overview]	Change From Baseline in Contrast Sensitivity in the Study Eye
NCT00658619 (5) [back to overview]	Change From Baseline in Reading Speed in the Study Eye
NCT00658619 (5) [back to overview]	Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
NCT00658619 (5) [back to overview]	Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
NCT00661479 (2) [back to overview]	Change From Baseline in Contrast Sensitivity in the Study Eye
NCT00661479 (2) [back to overview]	Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
NCT00693485 (2) [back to overview]	Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
NCT00693485 (2) [back to overview]	Percentage of Patients With a Visual Field Improvement in the Study Eye
NCT00697541 (3) [back to overview]	Tmax - Time to Maximum Plasma Concentration
NCT00697541 (3) [back to overview]	Cmax - Maximum Systemic Concentration of Brimonidine
NCT00697541 (3) [back to overview]	AUC - Area Under the Curve of Brimonidine
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 12
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 12
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 6
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 6
NCT00735449 (5) [back to overview]	Number of Subjects With Adverse Events
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Diastolic Blood Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
NCT00811564 (1) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery
NCT00824824 (1) [back to overview]	Presence of Retinal Vascular Dysregulation (RVD)
NCT00869141 (3) [back to overview]	Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma
NCT00869141 (3) [back to overview]	Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase
NCT00869141 (3) [back to overview]	Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma
NCT00961649 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, +2 Hrs, +7 Hrs, and +9 Hrs) at Week 6 - Brinz/Brim, Brinz+Brim
NCT00961649 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, + 2 Hrs, + 7 Hrs, and + 9 Hrs) at Week 6 - Brinz/Brim, Brinz, Brim
NCT00972374 (3) [back to overview]	Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
NCT00972374 (3) [back to overview]	Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
NCT00972374 (3) [back to overview]	Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit
NCT01062971 (2) [back to overview]	Intraocular Pressure (IOP)
NCT01062971 (2) [back to overview]	Number of Adverse Events
NCT01105065 (2) [back to overview]	Presence of Retinal Blood Flow Autoregulation
NCT01105065 (2) [back to overview]	Frequency Doubling Perimetry
NCT01144494 (5) [back to overview]	Supine Night-time & Day-time Seated Episcleral Venous Pressure (EVP)
NCT01144494 (5) [back to overview]	Outflow Facility
NCT01144494 (5) [back to overview]	Uveoscleral Outflow
NCT01144494 (5) [back to overview]	Aqueous Flow
NCT01144494 (5) [back to overview]	Seated Day-time IOP 9 am and 11 am, Supine Day-time IOP 9 am and 11 am, and Seated Night-time IOP 9 pm and 11 pm
NCT01170884 (1) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 12
NCT01216943 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test
NCT01229410 (3) [back to overview]	Highest Aqueous Humor Level of Brimonidine in the Study Eye
NCT01229410 (3) [back to overview]	Highest Vitreous Humor Level of Brimonidine in the Study Eye
NCT01229410 (3) [back to overview]	Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)
NCT01229462 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12
NCT01241240 (3) [back to overview]	Mean Worse Eye IOP
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye IOP
NCT01255306 (2) [back to overview]	Retinal Nerve Fiber Layer Thickness Change in Patients With Raised Intraocular Pressure Secondary to Silicone Oil Endotamponade
NCT01255306 (2) [back to overview]	Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography
NCT01297517 (1) [back to overview]	Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h)
NCT01297920 (1) [back to overview]	Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3
NCT01309204 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT01310777 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT01426867 (1) [back to overview]	Mean Ocular Discomfort Score
NCT01525173 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
NCT01659853 (2) [back to overview]	Composite Success
NCT01659853 (2) [back to overview]	Onset of Action
NCT01863953 (3) [back to overview]	Change From Baseline in Average Eye Mean Diurnal IOP
NCT01863953 (3) [back to overview]	Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)
NCT01863953 (3) [back to overview]	Average Eye Mean Diurnal IOP
NCT01885000 (9) [back to overview]	EuroQuality of Life-5 Dimensional-3 Level (EQ-5D-3L) Questionnaire at Day 8
NCT01885000 (9) [back to overview]	Percentage of Participants With Facial Redness Questionnaire at Day 8
NCT01885000 (9) [back to overview]	Change From Baseline in Facial Inflammatory Lesion Counts at Day 8
NCT01885000 (9) [back to overview]	Euro Quality of Life-5 Dimensional-3 Level (EQ-5D-3L) Questionnaire (Along With a Visual Analogue Score for the Overall Health State) at Day 8
NCT01885000 (9) [back to overview]	Number of Participants Reported Adverse Events
NCT01885000 (9) [back to overview]	Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment
NCT01885000 (9) [back to overview]	Percent Change From Baseline in Total Score of Dermatology Life Quality Index (DLQI) Questionnaire at Day 8
NCT01885000 (9) [back to overview]	Percentage of Participants With at Least Two Grade Improvement in the Clinician's Erythema Assessment (CEA)
NCT01885000 (9) [back to overview]	Percentage of Participants With at Least Two Grade Improvement in the Participant Self-assessment
NCT01937299 (3) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean IOP at Week 6 for Each Time Point (8 AM, 10 AM, 3 PM, 5 PM)
NCT01959230 (3) [back to overview]	Change From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale
NCT01959230 (3) [back to overview]	Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale
NCT01959230 (3) [back to overview]	Ocular Redness as Measured by the Participant
NCT01959243 (3) [back to overview]	Number of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29
NCT01959243 (3) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01959243 (3) [back to overview]	Drop Comfort Assessment as Assessed by the Participant
NCT01978600 (3) [back to overview]	Mean 24-hour IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Diurnal IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Nocturnal IOP at Week 4
NCT01987752 (2) [back to overview]	Percentage of Participants Reporting Adverse Events
NCT01987752 (2) [back to overview]	Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
NCT02003534 (1) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
NCT02087085 (3) [back to overview]	Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24
NCT02087085 (3) [back to overview]	Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24
NCT02087085 (3) [back to overview]	Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24
NCT02147691 (20) [back to overview]	IGA
NCT02147691 (20) [back to overview]	IGA
NCT02147691 (20) [back to overview]	Investigator Global Assessment (IGA) at Baseline
NCT02147691 (20) [back to overview]	Lesion Count
NCT02147691 (20) [back to overview]	Lesion Counts
NCT02147691 (20) [back to overview]	Lesion Counts
NCT02147691 (20) [back to overview]	Lesion Counts
NCT02147691 (20) [back to overview]	VAS
NCT02147691 (20) [back to overview]	VAS
NCT02147691 (20) [back to overview]	Visual Analog Scale (VAS)
NCT02147691 (20) [back to overview]	Clinician's Erythema Assessment
NCT02147691 (20) [back to overview]	Dermatology Life Quality Index (DLQI)
NCT02147691 (20) [back to overview]	Dermatology Life Quality Index (DLQI)
NCT02147691 (20) [back to overview]	DLQI
NCT02147691 (20) [back to overview]	DLQI
NCT02147691 (20) [back to overview]	Erythema
NCT02147691 (20) [back to overview]	Erythema
NCT02147691 (20) [back to overview]	Erythema
NCT02147691 (20) [back to overview]	Erythema Visual Analog Scale (VAS) Assessment (Subject)
NCT02147691 (20) [back to overview]	IGA
NCT02249065 (5) [back to overview]	Facial Redness Visual Analog Scale (VAS)
NCT02249065 (5) [back to overview]	Subject Facial Redness Questionnaire
NCT02249065 (5) [back to overview]	Inflammatory Lesions
NCT02249065 (5) [back to overview]	Subject Treatment Satisfaction Questionnaire
NCT02249065 (5) [back to overview]	Pre-Treatment Clinician Erythema Assessment (CEA)
NCT02289352 (2) [back to overview]	Primary: Percentage of Treatment Success on Day 7
NCT02289352 (2) [back to overview]	Percentage of Patients With a Clinical Response of Treatment Success on Day 1
NCT02339584 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT02385240 (3) [back to overview]	Proportion of Subjects With Composite Success
NCT02385240 (3) [back to overview]	Proportion of Subjects With Composite Success
NCT02385240 (3) [back to overview]	Proportion of Subjects With Composite Success
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 09:00 at Week 6
NCT02616250 (1) [back to overview]	Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):
NCT02730871 (5) [back to overview]	Mean Change From Baseline in Diurnal Intraocular Pressure (IOP) (Mean of Changes at 09:00 and 11:00 Time Points) at Week 6
NCT02730871 (5) [back to overview]	Mean Diurnal IOP at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in 24-hr Intraocular Pressure (IOP) at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in Daytime IOP at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in Nocturnal IOP at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in IOP for Each Time Point (8 AM Through 6 AM) at Week 4
NCT02975557 (1) [back to overview]	Primary Tolerability End Point: The Test Substance Tolerance (Visual Analog Scale) at 12 Weeks.
NCT03048058 (6) [back to overview]	Adherence (% of Prescribed Doses That Were Actually Taken by the Subject)
NCT03048058 (6) [back to overview]	Clinician Erythema Assessment Scale
NCT03048058 (6) [back to overview]	Lesion Count
NCT03048058 (6) [back to overview]	Patient Severity Assessment (PSA)
NCT03048058 (6) [back to overview]	Quality of Life (Measured by General Survey of Impact of Rosacea on Everyday Activities)
NCT03048058 (6) [back to overview]	Quality of Life With Rosacea
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 3 Hours After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 24 Hourw After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 1 Week After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 1 Hour After Nd-YAG Posterior Capsulotomy
NCT03257813 (8) [back to overview]	Number of Eyes With Tearing
NCT03257813 (8) [back to overview]	Intraocular Pressure (IOP)
NCT03257813 (8) [back to overview]	Visual Acuity (VA)
NCT03257813 (8) [back to overview]	Number of Eyes With Foreign Body Sensation
NCT03257813 (8) [back to overview]	Eye Burning
NCT03257813 (8) [back to overview]	Conjunctival Hyperemia
NCT03257813 (8) [back to overview]	Chemosis
NCT03257813 (8) [back to overview]	Adverse Events
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Changes in Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03418727 (1) [back to overview]	Tolerance of Test Substance Visual Analogue Scale (VAS) Score
NCT03450629 (1) [back to overview]	Change From Baseline in Mean Intraocular Pressure
NCT03591874 (3) [back to overview]	Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score
NCT03591874 (3) [back to overview]	Change From Baseline to Day 84 in Ocular Discomfort Visual Analog Scale (VAS) Score
NCT03591874 (3) [back to overview]	Change From Baseline to Day 84 in Symptom Assessment iN Dry Eye (SANDE) Questionnaire Scores
NCT03760185 (2) [back to overview]	Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye
NCT03760185 (2) [back to overview]	Change in Pupil Diameter of Each Eye After Dilation at the Start of the Study Compared to Pupil Post Dilating Drops at the End of the Study
NCT03782701 (4) [back to overview]	Eye Redness
NCT03782701 (4) [back to overview]	Intraocular Pressure
NCT03782701 (4) [back to overview]	Palpebral Fissure Height
NCT03782701 (4) [back to overview]	Eye Discomfort
NCT03785340 (4) [back to overview]	Change From Baseline to 2 Weeks (Day 14) in Lissamine Green Conjunctival Staining Scores
NCT03785340 (4) [back to overview]	Change From Baseline to 2 Weeks (Day 14) in SANDE Score
NCT03785340 (4) [back to overview]	Change From Baseline to 4 Weeks (Day 28) in Lissamine Green Conjunctival Staining Scores
NCT03785340 (4) [back to overview]	Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score
NCT03966365 (7) [back to overview]	Number of Adverse Events
NCT03966365 (7) [back to overview]	Participants With Chemosis
NCT03966365 (7) [back to overview]	Visual Ability
NCT03966365 (7) [back to overview]	Number of Eyes With Epithelial Defects by Grade
NCT03966365 (7) [back to overview]	Participants With Conjunctival Hyperemia (CH) by Grade
NCT03966365 (7) [back to overview]	Changes in Intraocular Pressure
NCT03966365 (7) [back to overview]	Eye Comfort Index

Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

IOP for a 24-hour period separated into diurnal(7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eye. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period. (NCT00457795)
Timeframe: Week 4

Intervention	Millimeters of mercury (mmHg) (Mean)
	Diurnal IOP Sitting at Week 4	Diurnal IOP Supine at Week 4	Nocturnal IOP Supine at Week 4
Brimonidine 0.1%	16.8	21.1	23.0

Intervention	Millimeters of mercury (mmHg) (Mean)
	Diurnal OPP Sitting at Week 4	Diurnal OPP Supine at Week 4	Nocturnal OPP Supine at Week 4
Brimonidine 0.1%	46.8	53.8	49.2

Intervention	Millimeters of mercury (mmHg) (Mean)
	Diurnal Change in OPP Sitting at Week 4	Diurnal Change in OPP Supine at Week 4	Nocturnal Change in OPP Supine at Week 4
Brimonidine 0.1%	1.1	0.3	-3.0

Intervention	Millimeters of mercury (mmHg) (Mean)
	Diurnal IOP Sitting at Baseline	Diurnal IOP Supine at Baseline	Nocturnal IOP Supine at Baseline	Diurnal IOP Sitting Change from Baseline at Week 4	Diurnal IOP Supine Change from Baseline at Week 4	Nocturnal IOP Supine Change from Baseline at Wk 4
Brimonidine 0.1%	19.2	23.1	22.7	-2.4	-1.9	0.3

Intervention	Number of Letters Read Correctly (Mean)
	Baseline	Change from Baseline at 24 Months
200 µg Brimonidine Tartrate Implant Stage 2	52.1	-3.2
400 µg Brimonidine Tartrate Implant Stage 2	54.8	-5.0
Sham (no Implant) Stage 2	53.7	-3.3

Intervention	Disc Area (Mean)
	Baseline	Change from Baseline at Month 12
200 µg Brimonidine Tartrate Implant Stage 2	6.897	1.006
400 µg Brimonidine Tartrate Implant Stage 2	6.219	0.898
Sham (no Implant) Stage 2	5.526	1.239

Intervention	Disc Area (Mean)
	Baseline	Change from Baseline at Month 3	Change from Baseline at Month 6	Change from Baseline at Month 9	Change from Baseline at Month 18	Change from Baseline at Month 24
200 µg Brimonidine Tartrate Implant Stage 2	6.897	0.117	0.570	0.798	1.413	1.991
400 µg Brimonidine Tartrate Implant Stage 2	6.219	0.182	0.482	0.641	1.306	1.744
Sham (no Implant) Stage 2	5.526	0.399	0.609	0.857	1.697	2.178

Intervention	Number of Letters Read Correctly (Mean)
	Baseline	Change from Baseline at Month 6
100 µg Brimonidine Tartrate Implant Group A	3.0	-2.0
100 µg Brimonidine Tartrate Implant Group B	22.3	4.3
200 µg Brimonidine Tartrate Implant Group B	18.0	-0.3
400 µg Brimonidine Tartrate Implant Group B	15.5	0.8

Intervention	Number of Letters Read Correctly (Mean)
	Baseline	Change from Baseline at Month 6
200 ug Brimonidine Implant	80.6	-2.2
400 ug Brimonidine Implant	76.0	2.8
Sham (no Implant)	77.3	0.3

Intervention	Percentage of Patients (Number)
400 ug Brimonidine Implant	12.0
200 ug Brimonidine Implant	9.5
Sham (no Implant)	4.2

Intervention	Hours (Mean)
Treatment A - COL-118 Facial Gel + Saline Drops	NA
Treatment B - Vehicle Gel + Brimonidine Drops	NA

Intervention	mmHg (millimeters of mercury) (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm	12:00 am	3:00 am	6:00 am
AZARGA	-3.3	-3.5	-1.5	-0.5	-1.4	-1.5	-0.5
COMBIGAN	0.6	-4.3	-0.9	-2.1	-7.3	-3.8	-0.7

Intervention	cm/s (centimeters per second) (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm	12:00 am	3:00 am	6:00 am
AZARGA	-0.0	-0.6	0.5	0.4	-0.8	-0.1	-0.2
COMBIGAN	-0.8	-1.2	0.2	-0.8	-1.4	-0.6	-0.5

Intervention	Arbitrary Units (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm
AZARGA	-272.4	-12.1	-26.7	14.0
COMBIGAN	-43.5	248.9	-51.3	-33.2

Intervention	mmHg (millimeters of mercury) (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm	12:00 am	3:00 am	6:00 am
AZARGA	-4.2	-2.6	-2.9	-1.4	-2.9	-2.9	-0.1
COMBIGAN	4.5	-1.9	-0.4	-0.6	-12.2	-3.0	3.0

Intervention	pg*hr/mL (Mean)
Treatment A - COL-118 Gel + Saline Drops	NA
Treatment B - Vehicle Gel + Brimonidine Drops	NA

Intervention	Millimeters of mercury (mm Hg) (Mean)
Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate	17.75
Latanoprost 0.005% Ophthalmic Solution	17.90

Intervention	mmHg in 1 year postop (Mean)
Hypertensive Phase Group	15.1
Non-hypertensive Phase Group	11.4

Intervention	millimeters mercury (mmHg) (Least Squares Mean)
	Change from Baseline (BL) at 8 AM	Change from BL at +2 hours relative to 8 AM dosing	Change from BL at +7 hours relative to 8 AM dosing	Change from BL at +9 hours relative to 8 AM dosing
Brinz/Brim	-5.5	-8.4	-5.0	-6.3
Brinz+Brim	-5.7	-8.3	-4.4	-6.3

Intervention	Percentage of Patients (Number)
400 ug Brimonidine Implant	20.0
200 ug Brimonidine Implant	26.7
Sham (no Implant)	28.6

Intervention	mmHg (Mean)
	baseline	Final
A (Triple Therapy)	24.1	13.9
B (Doble Therapy)	23.6	16.9

Intervention	dB (Mean)
RVD Patients Pre-brimonidine Treatment	-2.03
RVD Patients Post-brimonidine Treatment	-2.77

Intervention	mmHg (Mean)
	Daytime Seated	Nighttime Supine
Artificial Tears	10.3	11.2
Intraocular Pressure Lowering Drug	10.3	11.3

Intervention	μL/min (Mean)
IOP Lowering Drug (Day)	0.28
IOP Lowering Drug (Night)	0.28
Artificial Tears (Day)	0.29
Artificial Tears (Night)	0.29

Intervention	µl/min (Mean)
	day-time measurement	night-time measurement
Artificial Tears	2.3	1.5
IOP Lowering Drug	2.4	1.5

brimonidine tartrate

Description

Cross-References

Synonyms (25)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (1,501)

Study Types

Clinical Trials (160)

Trial Overview

Trial Outcomes

Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4

Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4

Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

Change From Baseline in Contrast Sensitivity in the Study Eye

Change From Baseline in Reading Speed in the Study Eye

Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

Change From Baseline in Contrast Sensitivity in the Study Eye

Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

Percentage of Patients With a Visual Field Improvement in the Study Eye

Tmax - Time to Maximum Plasma Concentration

Cmax - Maximum Systemic Concentration of Brimonidine

AUC - Area Under the Curve of Brimonidine

Mean Intraocular Pressure (IOP) at 8 AM at Week 12

Mean Intraocular Pressure (IOP) at 10 AM at Week 12

Mean Intraocular Pressure (IOP) at 10 AM at Week 6

Mean Intraocular Pressure (IOP) at 8 AM at Week 6

Number of Subjects With Adverse Events

Mean Change From Baseline in Diastolic Blood Pressure at Week 6

Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6

Mean Change From Baseline in Systolic Blood Pressure at Week 6

Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks

Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6

Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6

Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6

Intraocular Pressure (IOP) at Week 12

Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery

Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery

Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery

Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery

Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery

Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery

Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery

Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery

Presence of Retinal Vascular Dysregulation (RVD)

Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma

Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase

Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma

Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, +2 Hrs, +7 Hrs, and +9 Hrs) at Week 6 - Brinz/Brim, Brinz+Brim

Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, + 2 Hrs, + 7 Hrs, and + 9 Hrs) at Week 6 - Brinz/Brim, Brinz, Brim

Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit

Intraocular Pressure (IOP)

Number of Adverse Events

Presence of Retinal Blood Flow Autoregulation

Frequency Doubling Perimetry

Supine Night-time & Day-time Seated Episcleral Venous Pressure (EVP)

Outflow Facility

Uveoscleral Outflow

Aqueous Flow

Seated Day-time IOP 9 am and 11 am, Supine Day-time IOP 9 am and 11 am, and Seated Night-time IOP 9 pm and 11 pm

Mean Diurnal Intraocular Pressure (IOP) at Week 12

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye

Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)

Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure

Intervention	mmHg (Mean)
	Seated day-time 9 am	Seated day-time 11 am	Supine day-time 9 am	Supine day-time 11 am	Seated night-time 9 pm	Seated night-time 11 pm
Artificial Tears	20.3	19.9	25.4	24.7	18.0	18.4
Intraocular Pressure Lowering Drug	18.1	18.0	23.1	23.1	16.0	16.7

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 12
Triple Combination Therapy	22.35	-3.98

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 1 (N=82, 91)	Change from Baseline at Week 2 (N=84, 92)	Change from Baseline at Week 4 (N=85, 93)	Change from Baseline at Week 8 (N=85, 93)	Change from Baseline at Week 12 (N=85, 93)	Change from Baseline at Month 6 (N=67, 73)	Change from Baseline at Month 9 (N=67, 73)	Change from Baseline at Month 12 (N=67, 73)
Combigan®	24.43	-8.13	-8.28	-8.53	-8.07	-8.28	-8.42	-8.17	-7.77
Triple Combination Therapy	25.42	-11.63	-11.20	-10.85	-10.44	-10.45	-10.32	-10.09	-9.36

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 1 (N=82, 91)	Change from Baseline at Week 2 (N=82, 87)	Change from Baseline at Week 4 (N=82, 88)	Change from Baseline at Week 8 (N=75, 87)	Change from Baseline at Week 12 (N=76, 83)	Change from Baseline at Month 6 (N=64, 69)	Change from Baseline at Month 9 (N=58, 67)	Change from Baseline at Month 12 (N=55, 63)
Combigan®	24.43	-8.13	-8.12	-8.35	-7.94	-8.16	-8.29	-8.14	-7.58
Triple Combination Therapy	25.42	-11.63	-11.24	-10.88	-10.53	-10.56	-10.41	-10.29	-9.38

Intervention	Nanogram/milliliter (ng/mL) (Number)
400 µg Brimonidine Tartrate Implant	17.5
200 µg Brimonidine Tartrate Implant	12.5

Intervention	Nanogram/milliliter (ng/mL) (Number)
400 µg Brimonidine Tartrate Implant	137.0
200 µg Brimonidine Tartrate Implant	34.9

Intervention	Percentage of Patient Samples (Number)
400 µg Brimonidine Tartrate Implant	53.3
200 µg Brimonidine Tartrate Implant	72.6

Intervention	mm Hg (Mean)
	Baseline	Change from baseline at Week 4
Alphagan® and Timolol Concurrent	24.53	-5.70
Combigan®	25.07	-6.21

Intervention	mmHg (Mean)
	Baseline (n=93,95)	Change from Baseline at Week 12 (n=93,94)
Combigan®	25.12	-9.18
Triple Combination Therapy	24.62	-10.03

Intervention	mmHg (Mean)
	Week 1 (n=91,90)	Week 2 (n=88,95)	Week 4 (n=86,92)	Week 8 (n=88,91)	Week 12 (n=86,88)
Combigan®	16.23	16.08	15.96	16.11	15.92
Triple Combination Therapy	14.43	14.05	14.38	14.68	14.43